Page 44 - SAMENA Trends - November-December 2019

REGIONAL & MEMBERS UPDATES SAMENA TRENDS

goetzpartners Advised ITM on a Technology
License Agreement for Medical Radioisotopes

with CIRC in China

goetzpartners advised ITM Isotopen Technologien München the next step in serving Chinese cancer patients through China’s
AG (ITM), a biotechnology and radiopharmaceutical group of nuclear medicine practitioners in a better and timely manner
companies on a technology license agreement with Chengdu and deepening our relationship with ITM at the same time.
Gaotong Isotope Co., Ltd. a subsidiary of China Isotope & We believe that on the basis of our decades of experiences in
Radiation Corporation (CIRC), a nuclear technology application radionuclides and radiopharmaceutical research and production,
products manufacturer and supplier. The agreement is in relation by manufacturing radioisotopes according to the unique
to the production and distribution of Germanium-68/Gallium-68 methodologies developed by ITM and internationally accepted
Generators and no-carrier-added (n.c.a) Lutetium-177 quality standards, particularly the theranostic pair Gallium-68 and
(EndolucinBeta®) in China. ITM and CIRC have already been the unrivaled no-carrier-added Lutetium-177, we will be able to
working together in a successful partnership for almost 10 years supply high quality products to help many cancer patients in China
in which CIRC has distributed ITM‘s medical radioisotopes, and provide an economically sustainable solution for the Chinese
generators, and equipment to the Chinese market. China’s Health Care System.“ goetzpartners Corporate Finance acted as
radiopharmaceutical market is now growing rapidly in line with the exclusive advisor to ITM, further underlining our competence as
fast expanding clinical evidence and use of Targeted Radionuclide advisor of choice in the healthcare industry and in cross-border
Therapies worldwide. In order to meet the rising demand for transactions. Additional terms of the agreement are not disclosed.
Targeted Radionuclide Therapy in China, ITM and CIRC have
decided to enter into a technology license agreement. Under the
terms of the agreement, CIRC’s subsidiary Gaotong will implement
the production of 68Ge/68Ga Generators and n.c.a. Lutetium-177
(EndolucinBeta®), in China for the Chinese market, as well as
joining ITM’s global network of OEM suppliers in support of ITM’s
international framework agreements with strategic partners. With
this new partnership, CIRC is now the fourth partner to join the
global ITM OEM Processing and Production Network. “ITM has
developed a strong presence in the Chinese market through CIRC
as our distribution partner, supplying 68Ge/68Ga Generators
and no-carrier-added Lutetium-177 since 2010”, said Steffen
Schuster, CEO of ITM. “Now we are excited to take our established
partnership to the next level. This agreement with CIRC allows
us to share our manufacturing expertise in producing high-
quality theranostic radioisotopes with a reliable partner who is
able to implement and set highest quality standards in China.
This gives us the opportunity to provide locally manufactured
radioisotopes for Chinese cancer patients and also for cancer
patients worldwide via our OEM Network. Through this expanded
relationship with CIRC and Gaotong, we are looking forward to
making Targeted Radionuclide Therapy available to a growing
number of cancer patients and to jointly improving patients’
outcomes and quality of life.” Mr. Wu Jian, General Manager of
CIRC added: “We can look back on a long-standing and reliable
relationship with ITM through which we have been able to offer
the best next-generation medical isotope products available
to the emerging Chinese radiopharmaceutical market from the
very beginning. With this important agreement, we are taking

44 NOVEMBER 2019